Hikma Pharmaceuticals 

$42.04
465
-$2.21-4.99% Friday 19:24

Statistics

Day High
42.59
Day Low
42.59
52W High
55.33
52W Low
31.8
Volume
100
Avg. Volume
193
Mkt Cap
9.87B
P/E Ratio
11.38
Dividend Yield
4%
Dividend
1.68

Upcoming

Dividends

4%Dividend Yield
May 26
$0.96
Sep 25
$0.72
May 25
$0.96
Sep 24
$0.64
May 24
$0.94
10Y Growth
10.13%
5Y Growth
10.07%
3Y Growth
10.65%
1Y Growth
N/A

Earnings

6AugExpected
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
75.82
83.76
91.7
99.63
Expected EPS
83.57216
Actual EPS
N/A

Financials

12%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.35BRevenue
402MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HKMPY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, directly competing with Hikma in the generics and branded drugs markets.
Novartis
NVS
Mkt Cap305.1B
Novartis is a large multinational pharmaceutical company with a strong presence in generic drugs through its Sandoz division, making it a direct competitor to Hikma.
Pfizer
PFE
Mkt Cap138.61B
Pfizer is a global pharmaceutical corporation with a broad portfolio that includes generic drugs, competing with Hikma in various therapeutic areas.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie, known for its significant research-based pharmaceuticals, competes with Hikma in the specialty pharmaceuticals market, particularly in areas like immunology and oncology.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes with Hikma in the development and marketing of pharmaceuticals for various therapeutic areas.
Merck
MRK
Mkt Cap319.99B
Merck & Co. is a global healthcare company that competes with Hikma in the development, manufacturing, and marketing of pharmaceuticals and vaccines.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline is a global healthcare company that competes with Hikma in the pharmaceutical and vaccines sectors, with a broad portfolio of products.
Sanofi
SNY
Mkt Cap103.32B
Sanofi is a global pharmaceutical company that competes with Hikma in the areas of generics, specialty care, and vaccines.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Hikma in the development and commercialization of prescription medicines across multiple therapy areas.

About

Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and other non-injectable generic formulations to the retail market. The Branded segment, conversely, delivers branded generic drugs and products licensed from third parties to both retail consumers and hospitals. Hikma's product portfolio addresses numerous therapeutic areas, such as anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory illnesses. The company maintains a substantial international footprint, operating throughout the United Kingdom, the United States, the Middle East, North Africa, Europe, and other global markets. Founded in 1978, Hikma Pharmaceuticals PLC has its headquarters in London, UK.
Show more...
CEO
H.E Said Samih Taleb Darwazah
Employees
9500
Country
United Kingdom
ISIN
US4312881091

Listings

0 Comments

Share your thoughts

FAQ

What is Hikma Pharmaceuticals stock price today?
The current price of HKMPY is $42.04 USD — it has decreased by -4.99% in the past 24 hours. Watch Hikma Pharmaceuticals stock price performance more closely on the chart.
What is Hikma Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Hikma Pharmaceuticals stocks are traded under the ticker HKMPY.
Is Hikma Pharmaceuticals stock price growing?
HKMPY stock has risen by +0.13% compared to the previous week, the month change is a +3.75% rise, over the last year Hikma Pharmaceuticals has showed a -21.39% decrease.
What is Hikma Pharmaceuticals market cap?
Today Hikma Pharmaceuticals has the market capitalization of 9.87B
When is the next Hikma Pharmaceuticals earnings date?
Hikma Pharmaceuticals is going to release the next earnings report on August 06, 2026.
What is Hikma Pharmaceuticals revenue for the last year?
Hikma Pharmaceuticals revenue for the last year amounts to 3.35B USD.
What is Hikma Pharmaceuticals net income for the last year?
HKMPY net income for the last year is 402M USD.
Does Hikma Pharmaceuticals pay dividends?
Yes, HKMPY dividends are paid semi-annual. The last dividend per share was 0.96 USD. As of today, Dividend Yield (FWD)% is 4%.
How many employees does Hikma Pharmaceuticals have?
As of July 11, 2026, the company has 9,500 employees.
In which sector is Hikma Pharmaceuticals located?
Hikma Pharmaceuticals operates in the Health & Wellness sector.
When did Hikma Pharmaceuticals complete a stock split?
Hikma Pharmaceuticals has not had any recent stock splits.
Where is Hikma Pharmaceuticals headquartered?
Hikma Pharmaceuticals is headquartered in London, United Kingdom.